title: Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice.
abstract: Acute promyelocytic leukemia (APL) is associated with reciprocal chromosomal translocations involving the retinoic acid receptor alpha (RARalpha) locus on chromosome 17. In the majority of cases, RARalpha translocates and fuses with the promyelocytic leukemia (PML) gene located on chromosome 15. The resulting fusion genes encode the two structurally unique PML/RARalpha and RARalpha/PML fusion proteins as well as aberrant PML gene products, the respective pathogenetic roles of which have not been elucidated. We have generated transgenic mice in which the PML/RARalpha fusion protein is specifically expressed in the myeloid-promyelocytic lineage. During their first year of life, all the PML/RARalpha transgenic mice have an abnormal hematopoiesis that can best be described as a myeloproliferative disorder. Between 12 and 14 months of age, 10% of them develop a form of acute leukemia with a differentiation block at the promyelocytic stage that closely mimics human APL even in its response to retinoic acid. Our results are conclusive in vivo evidence that PML/RARalpha plays a crucial role in the pathogenesis of APL.
authors.affiliation: Department of Human Genetics, Memorial Sloan-Kettering Cancer Center, Molecular Biology and Cell Biology Programs, Sloan-Kettering Institute, 1275 York Avenue, New York, NY, 10021, USA.
authors.forename: L Z
authors.initials: LZ
authors.lastname: He
authors.forename: C
authors.initials: C
authors.lastname: Tribioli
authors.forename: R
authors.initials: R
authors.lastname: Rivi
authors.forename: D
authors.initials: D
authors.lastname: Peruzzi
authors.forename: P G
authors.initials: PG
authors.lastname: Pelicci
authors.forename: V
authors.initials: V
authors.lastname: Soares
authors.forename: G
authors.initials: G
authors.lastname: Cattoretti
authors.forename: P P
authors.initials: PP
authors.lastname: Pandolfi
mesh_terms: D000375:Aging; D000818:Animals; D001772:Blood Cell Count; D001853:Bone Marrow / Q000473:pathology; D002454:Cell Differentiation / Q000187:drug effects; D002886:Chromosomes, Human, Pair 17; D017931:DNA Primers; D006410:Hematopoiesis; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000187:drug effects / Q000473:pathology; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000097:blood / Q000235:genetics* / Q000473:pathology; D008214:Lymphocytes / Q000166:cytology / Q000187:drug effects / Q000473:pathology; D051379:Mice; D008822:Mice, Transgenic; D009196:Myeloproliferative Disorders / Q000235:genetics / Q000503:physiopathology; D009363:Neoplasm Proteins; D009687:Nuclear Proteins; D016133:Polymerase Chain Reaction; D000071156:Promyelocytic Leukemia Protein; D018168:Receptors, Retinoic Acid / Q000096:biosynthesis / Q000235:genetics*; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis*; D012016:Reference Values; D000072482:Retinoic Acid Receptor alpha; D013154:Spleen / Q000473:pathology; D014157:Transcription Factors / Q000096:biosynthesis / Q000235:genetics*; D014178:Translocation, Genetic; D014212:Tretinoin / Q000494:pharmacology; D025521:Tumor Suppressor Proteins
chemical_list: D017931:DNA Primers; D009363:Neoplasm Proteins; D009687:Nuclear Proteins; C513293:Pml protein, mouse; D000071156:Promyelocytic Leukemia Protein; C000607071:RARA protein, human; C000607072:Rara protein, mouse; D018168:Receptors, Retinoic Acid; D011993:Recombinant Fusion Proteins; D000072482:Retinoic Acid Receptor alpha; D014157:Transcription Factors; D025521:Tumor Suppressor Proteins; C070576:PML protein, human; D014212:Tretinoin